0000899243-20-002644.txt : 20200203
0000899243-20-002644.hdr.sgml : 20200203
20200203205538
ACCESSION NUMBER: 0000899243-20-002644
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200201
FILED AS OF DATE: 20200203
DATE AS OF CHANGE: 20200203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fairey William
CENTRAL INDEX KEY: 0001727275
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37609
FILM NUMBER: 20570382
MAIL ADDRESS:
STREET 1: C/O CHEMOCENTRYX, INC.
STREET 2: 850 MAUDE AVE.
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MyoKardia Inc
CENTRAL INDEX KEY: 0001552451
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455500552
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-741-0900
MAIL ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-01
0
0001552451
MyoKardia Inc
MYOK
0001727275
Fairey William
C/O MYOKARDIA, INC.
333 ALLERTON AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2020-02-01
4
M
0
8125
A
8125
D
Common Stock
2020-02-01
4
S
0
2899
68.04
D
5226
D
Restricted Stock Units
2020-02-01
4
M
0
8125
0.00
D
Common Stock
8125
24375
D
Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis.
Represents the number of shares of Issuer's Common Stock sold to cover the Reporting Person's withholding taxes in connection with the vesting of 8,125 shares of Common Stock underlying the Reporting Person's RSUs.
Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
Executive Vice President, Chief Commercial Officer
/s/ Cynthia Ladd, as Attorney-in-Fact
2020-02-03